Brief: Algernon Pharmaceuticals Receives Notice Of Allowance From The Japanese Patent Office For Repirinast And The Treatment Of CKD
31/05/2023 12:26
May 31 (Reuters) - Algernon Pharmaceuticals Inc
AGN.CD :
* ALGERNON PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FROM
THE
JAPANESE PATENT OFFICE FOR REPIRINAST AND THE TREATMENT OF CKD
Source text for Eikon: ID:nGNX5MZRPp
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement